Invitae (NVTAQ) Stock Price
Invitae Price
Invitae (NVTAQ) Stock | ISIN US46185L1035 | WKN A14NKG. The current Invitae stock price is 0 USD (2026). Market capitalization is 85,947 USD. Invitae operates in the Health sector.
Invitae stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Invitae over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Invitae stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Invitae's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Invitae Price |
|---|
Invitae Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Invitae Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|
| 216 | 279 | 460 | 516 | 498 | 539 | 592 | 614 |
| 46.94 | 29.17 | 64.87 | 12.17 | -3.49 | 8.23 | 9.83 | 3.72 |
| 45.37 | 29.03 | 24.13 | 21.9 | 22.69 | 20.96 | 19.09 | 18.4 |
| 98 | 81 | 111 | 113 | 113 | 113 | 113 | 113 |
| -242 | -602 | -379 | -3,106 | -300 | -261 | -220 | -247 |
| 87.6 | 148.76 | -37.04 | 719.53 | -90.34 | -13 | -15.71 | 12.27 |
| 90.9 | 134.6 | 210.9 | 235.7 | 235.7 | 235.7 | 235.7 | 235.7 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Invitae generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Invitae retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Invitae's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Invitae has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Invitae's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Invitae stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Invitae Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Invitae business model & stock analysis
Invitae SWOT Analysis
Strengths
Invitae Corp possesses several strengths that contribute to its success:
- Wide Range of Genetic Testing: Invitae offers a comprehensive portfolio of genetic tests, catering to various medical conditions and diseases.
- Advanced Technology: The company utilizes cutting-edge technology for accurate and reliable genetic testing results.
- Strong Partnerships: Invitae has established strategic partnerships with leading healthcare providers and pharmaceutical companies.
- Growing Customer Base: The company has witnessed significant growth in its customer base, indicating strong market demand for genetic testing services.
Weaknesses
Despite its strengths, Invitae Corp also faces certain weaknesses:
- Pricing Challenges: Genetic testing services can be expensive, which may limit the accessibility for some potential customers.
- Intense Competition: The genetic testing market is highly competitive, with numerous companies vying for market share.
- Regulatory Compliance: The company needs to comply with stringent regulations governing genetic testing, increasing operational complexities.
Opportunities
Invitae Corp can capitalize on the following opportunities:
- Market Expansion: The increasing awareness and adoption of genetic testing present opportunities for Invitae to expand its market presence.
- Technological Advancements: Advancements in genetic research and technology may create new testing opportunities for the company.
- Collaborations and Partnerships: Forming strategic collaborations and partnerships can help Invitae tap into new customer segments and markets.
Threats
Invitae Corp should be cautious about the following threats:
- Regulatory Risks: Changes in regulations and policies governing genetic testing may impact the company's operations and financials.
- New Entrants: The entry of new competitors in the genetic testing market can intensify competition and challenge Invitae's market position.
- Data Privacy Concerns: Maintaining data privacy and ensuring compliance with privacy regulations are critical, given the sensitive nature of genetic information.
Invitae Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Invitae historical P/E ratio, EBIT multiple, and P/S ratio
Invitae shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Invitae Earnings Estimates
Invitae Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 11/6/2024 | -0.21USD | 126.9 MUSD | 2024 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Invitae stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Invitae shareholder structure
| % | Name |
|---|---|
0.29669% | |
0.29669% | |
0.29669% | |
0.24013% | |
0.14494% | |
0.12114% | |
0.10706% | |
0.08224% | |
0.06841% | |
0.0643% |
Invitae Executives and Management Board
Mr. Kenneth Knight
(62)President, Chief Executive Officer, Director · since 2020
Mr. Thomas Brida
(52)Chief Compliance Officer, General Counsel, Secretary
Dr. Robert Nussbaum
(73)Chief Medical Officer
Dr. Sean George
(49)Director · since 2010
Dr. Eric Aguiar
(61)Lead Independent Director
Frequently asked questions about Invitae
The business model of Invitae Corp is focused on providing comprehensive genetic information to guide healthcare decisions. Invitae offers genetic testing services, including diagnostic testing for hereditary diseases and disorders, as well as proactive testing for healthy individuals. The company's goal is to make genetic information accessible and affordable, enabling personalized healthcare and aiding in clinical research. Invitae utilizes advanced technologies and a scalable platform to deliver high-quality, cost-effective genetic testing solutions. By empowering patients, physicians, and researchers with genetic insights, Invitae aims to improve the understanding, treatment, and prevention of genetic diseases.
Invitae stock
Invitae Peer Group
Invitae Ticker
Invitae FIGI
All fundamentals and in-depth analysis of Invitae
Our stock analysis for Invitae Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Invitae Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.